Meeting
2022 ASCO Annual Meeting
Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.
Authors
Andrew Spencer
Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
Andrew Spencer , Philippe Moreau , Maria-Victoria Mateos , Hartmut Goldschmidt , Kenshi Suzuki , Mark-David Levin , Pieter Sonneveld , Sung-Soo Yoon , Saad Zafar Usmani , Katja Weisel , Donna Ellen Reece , Tahamtan Ahmadi , Huiling Pei , Wendy Garvin Mayo , Xue Gai , Jodi Carey , Robin L. Carson , Meletios A. Dimopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02136134 and NCT02076009
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8052)
DOI
10.1200/JCO.2022.40.16_suppl.8052
Abstract #
8052
Poster Bd #
475
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
First Author: Pieter Sonneveld
Poster
2017 ASCO Annual Meeting
Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.
First Author: Maria-Victoria Mateos
Poster
2015 ASCO Annual Meeting
![Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).](https://d201v5jt9ylckg.cloudfront.net/156/9331/115161/115161_poster_pv.jpg)
Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).
First Author: Antonio Palumbo
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau